• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

DARZALEX (daratumumab) - Articles and news items

daratumumab

Janssen submits application to the EMA to expand use of DARZALEX® (daratumumab)

Industry news / 24 August 2016 / Janssen-Cilag International NV

Phase 3 data supporting submission suggests potential clinical benefit of daratumumab as a backbone therapy in combination with either a proteasome inhibitor (PI) or an immunomodulatory agent for relapsed multiple myeloma patients…

Daratumumab

Daratumumab significantly extends PFS in multiple myeloma study

Industry news / 10 June 2016 / Victoria White, Digital Content Producer

A Phase III trial shows daratumumab in combination with lenalidomide and dexamethasone achieved a 63% reduction in the risk of disease progression or death…

daratumumab

Daratumumab extends PFS in patients with multiple myeloma

Industry news / 6 June 2016 / Victoria White, Digital Content Producer

Daratumumab, in combination with bortezomib and dexamethasone, demonstrated a 61% reduction in the risk of disease progression or death…

daratumumab

EC grants conditional approval to daratumumab in multiple myeloma

Industry news / 23 May 2016 / Victoria White, Digital Content Producer

Daratumumab is the first CD38-directed mAb approved in Europe. It binds to CD38, a signalling molecule expressed on the surface of multiple myeloma cells…

Daratumumab

Daratumumab combination improves PFS in multiple myeloma study

Industry news / 1 April 2016 / Victoria White

Daratumumab combination treatment regimen improved progression-free survival compared with bortezomib and dexamethasone alone…

Daratumumab

Daratumumab and atezolizumab to be evaluated in two studies

Industry news / 22 March 2016 / Victoria White

The studies will assess the combination of daratumumab and atezolizumab in multiple myeloma and in solid tumour cancer…

Darzalex

FDA approves Darzalex for multiple myeloma

Industry news / 17 November 2015 / Victoria White

Darzalex (daratumumab) is the first human anti-CD38 monoclonal antibody (mAb) approved anywhere in the world…

multiple-myeloma-treatment-market

Global multiple myeloma treatment market value to rise to $22.4b by 2023

Industry news / 29 October 2015 / Victoria White

The global multiple myeloma treatment market will rise in value from $8.9 billion in 2014 to an estimated $22.4 billion by 2023, according to research and consulting firm GlobalData…

multiple-myeloma

Asia-Pacific multiple myeloma treatment market value to hit $2.8b by 2021

Industry news / 20 October 2015 / Victoria White

The treatment market for multiple myeloma across China, India, Japan, and Australia will rise in value from $1.7 billion in 2014 to $2.8 billion by 2021…

daratumumab

Janssen submits MAA for daratumumab to EMA

Industry news / 10 September 2015 / Victoria White

Daratumumab is an investigational, human anti-CD38 monoclonal antibody, for the treatment of patients with relapsed and refractory multiple myeloma…

Genmab logo office sign

Genmab announces preliminary results in Phase II study of Daratumumab in double refractory multiple myeloma

Industry news / 4 February 2015 / Genmab

Genmab A/S today announced preliminary results from the Phase II study of daratumumab in double refractory multiple myeloma conducted by its collaboration partner Janssen Biotech…

Genmab logo

Genmab announces new phase III combination study of Daratumumab in frontline multiple myeloma

Industry news / 10 November 2014 / Genmab A/S

Genmab A/S announced today that the French Intergroup of Myeloma (IFM) in collaboration with Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and Janssen Biotech, Inc. plans to start an additional Phase III study of daratumumab in frontline multiple myeloma…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +